Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists, issued a correction on April 28, 2026, to its earlier press release regarding its partnership with TARA Mind. The correction removes references to Veterans Exploring Treatment Solutions from earlier paragraphs while reaffirming the collaboration's goal to support Phase 3 recruitment for its HLP003 program in major depressive disorder and expand outreach in veteran communities.
The partnership is designed to align with a recent executive order aimed at advancing mental health treatments and increasing clinical research participation among veterans. Helus Pharma's HLP003, a proprietary novel serotonergic agonist, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and is currently in Phase 3 clinical development for the adjunctive treatment of major depressive disorder.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, is committed to developing synthetic molecules that activate serotonin pathways to promote neuroplasticity, addressing unmet needs in depression, anxiety, and other mental health conditions. The company's pipeline also includes HLP004, a proprietary NSA in Phase 2 for generalized anxiety disorder, and an extensive research portfolio of investigational NSAs.
The correction underscores Helus Pharma's focus on transparent communication as it advances its clinical programs. The company operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit the full press release here and the company's newsroom here.
